Cargando…
STX140, but Not Paclitaxel, Inhibits Mammary Tumour Initiation and Progression in C3(1)/SV40 T/t-Antigen Transgenic Mice
Despite paclitxael's clinical success, treating hormone-refractory breast cancer remains challenging. Paclitaxel has a poor pharmacological profile, characterized by a low therapeutic index (TIX) caused by severe dose limiting toxicities, such as neutropenia and peripheral neuropathy. Consequen...
Autores principales: | Meyer-Losic, Florence, Newman, Simon P., Day, Joanna M., Reed, Michael J., Kasprzyk, Philip G., Purohit, Atul, Foster, Paul A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855596/ https://www.ncbi.nlm.nih.gov/pubmed/24324595 http://dx.doi.org/10.1371/journal.pone.0080305 |
Ejemplares similares
-
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
por: Day, J M, et al.
Publicado: (2009) -
Simian virus 40 (SV40)-transgenic mice that develop tumors are specifically tolerant to SV40 T antigen
Publicado: (1987) -
Novel Anti-Acanthamoebic Activities of Irosustat and STX140 and Their Nanoformulations
por: Siddiqui, Ruqaiyyah, et al.
Publicado: (2023) -
Aberrant Proliferation of Differentiating Alveolar Cells Induces Hyperplasia in Resting Mammary Glands of SV40-TAg Transgenic Mice
por: Quante, Timo, et al.
Publicado: (2014) -
Hepatocarcinogenesis in Transgenic Mice Carrying Albumin‐promoted SV40 T Antigen Gene
por: Hino, Okio, et al.
Publicado: (1991)